Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa.
Despite the recent success of gene-based complementation approaches for genetic recessive traits, the development of therapeutic strategies for gain-of-function mutations poses great challenges. General therapeutic principles to correct these genetic defects mostly rely on post-transcriptional gene regulation (RNA silencing). Engineered zinc-finger (ZF) protein-based repression of transcription may represent a novel approach for treating gain-of-function mutations, although proof-of-concept of this use is still lacking. Here, we generated a series of transcriptional repressors to silence human rhodopsin (hRHO), the gene most abundantly expressed in retinal photoreceptors. The strategy was designed to suppress both the mutated and the wild-type hRHO allele in a mutational-independent fashion, to overcome mutational heterogeneity of autosomal dominant retinitis pigmentosa due to hRHO mutations. Here we demonstrate that ZF proteins promote a robust transcriptional repression of hRHO in a transgenic mouse model of autosomal dominant retinitis pigmentosa. Furthermore, we show that specifically decreasing the mutated human RHO transcript in conjunction with unaltered expression of the endogenous murine Rho gene results in amelioration of disease progression, as demonstrated by significant improvements in retinal morphology and function. This zinc-finger-based mutation-independent approach paves the way towards a 'repression-replacement' strategy, which is expected to facilitate widespread applications in the development of novel therapeutics for a variety of disorders that are due to gain-of-function mutations.
Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Claudio
C
Mussolino
Daniela
D
Sanges
Elena
E
Marrocco
Ciro
C
Bonetti
Umberto
U
Di Vicino
Valeria
V
Marigo
Alberto
A
Auricchio
Germana
G
Meroni
Enrico Maria
EM
Surace
D000818:Animals; D004195:Disease Models, Animal; D015536:Down-Regulation; D055785:Gene Knockdown Techniques / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009887:Ophthalmoscopy; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism*; D012174:Retinitis Pigmentosa / Q000235:genetics / Q000628:therapy*; D012243:Rhodopsin / Q000096:biosynthesis* / Q000235:genetics; D014158:Transcription, Genetic
D012097:Repressor Proteins; D012243:Rhodopsin
Am J Hum Genet. 2007 Jul;81(1):127-35
17564969
Mol Ther. 2007 May;15(5):912-20
17245354
Nat Med. 2002 Dec;8(12):1427-32
12415262
Nat Biotechnol. 2003 Mar;21(3):269-74
12592412
Hum Gene Ther. 2008 Oct;19(10):979-90
18774912
J Biol Chem. 2001 Aug 3;276(31):29466-78
11340073
Lancet. 2007 Jun 23;369(9579):2097-105
17586305
Nat Biotechnol. 2005 Jan;23(1):108-16
15619618
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14176-81
8943080
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11488-93
11005848
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17366-71
17088543
N Engl J Med. 2008 May 22;358(21):2231-9
18441371
Gene Ther. 2005 Aug;12(15):1223-8
15877050
Mol Ther. 2009 Apr;17(4):593-9
19174761
Nature. 2006 May 25;441(7092):537-41
16724069
N Engl J Med. 2009 Jan 29;360(5):447-58
19179314
Lancet. 2009 Nov 7;374(9701):1597-605
19854499
Curr Opin Biotechnol. 2001 Dec;12(6):632-7
11849947
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1432-6
11171968
Hum Mol Genet. 2001 Dec 15;10(26):3075-81
11751689
Nat Med. 1998 Aug;4(8):967-71
9701253
J Biol Chem. 2005 Feb 4;280(5):3707-14
15537646
J Biol Chem. 1996 Nov 8;271(45):28549-57
8910484
Neuron. 1997 Nov;19(5):1017-30
9390516
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2812-7
9501172
Gene Ther. 2008 Mar;15(6):463-7
18004402
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2758-63
10077584
Nat Rev Drug Discov. 2003 May;2(5):361-8
12750739
Nat Med. 2004 Aug;10(8):816-20
15235598
J Biol Chem. 2000 Oct 27;275(43):33850-60
10913152
Mol Ther. 2008 May;16(5):916-23
18388922
J Biol Chem. 2000 Nov 24;275(47):37264-70
10984472
J Mol Biol. 2000 Nov 3;303(4):489-502
11054286
Science. 2009 Nov 6;326(5954):818-23
19892975
J Med Genet. 1998 Jan;35(1):1-5
9475085
Mol Ther. 2009 Jan;17(1):169-75
19002161
N Engl J Med. 2008 May 22;358(21):2240-8
18441370
Hum Mutat. 2001;17(1):42-51
11139241
Mol Pharmacol. 2000 Jul;58(1):1-10
10860921
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W516-23
16845061
J Virol. 2007 Oct;81(20):11372-80
17699581
EMBO J. 2002 Mar 1;21(5):857-64
11867514
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):191-5
8552602
Mol Vis. 2007 Oct 02;13:1842-50
17960120
Proc Natl Acad Sci U S A. 1994 May 10;91(10):4509-13
8183939
PLoS One. 2007 Aug 22;2(8):e774
17712422
Mol Ther. 2005 Sep;12(3):555-61
15967729
J Biol Chem. 2005 Oct 21;280(42):35588-97
16107335
J Biol Chem. 2001 Apr 6;276(14):11323-34
11145970
Nature. 2008 Sep 11;455(7210):160-4
18784697
Mol Vis. 2005 Aug 29;11:648-56
16145542
EMBO J. 1992 Dec;11(13):4961-8
1464321
Nat Rev Genet. 2010 Apr;11(4):273-84
20212494
J Gene Med. 2008 Apr;10(4):375-82
18278824
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14628-33
9843940